Synthetic Genomics, Ceva partner to develop livestock vaccinesNovember 1, 2017 Synthetic Genomics Inc. announced that it has partnered with Ceva Santé Animale to utilize Synthetic Genomics' next-generation synthetic RNA replicon platform to develop vaccines for livestock. Synthetic Genomics' RNA replicons are programed to deliver genetic instructions to a body's own cells to unleash a powerful immune response against a specific disease, the company said. These RNA replicons carry the genetic code for a self-replication engine as well as antigens that signal for an immune response. The self-amplifying, RNA-based vaccine triggers rapid and immediate antigen expression within host cells, which induces strong T cell and B cell responses. These fully synthetic vaccines have lower dose requirements and simplified manufacturing compared to traditional vaccine approaches, according to the announcement. "We have made tremendous progress to date in programming RNA to develop next-generation vaccines that are multigenic, tunable and, most importantly, scalable for commercially competitive markets such as animal health," said Synthetic Genomics CEO Dr. Oliver Fetzer. "This partnership with Ceva, a leader in animal health, highlights the promise in deploying our synthetic biology capabilities to build RNA systems capable of improving global health in a variety of ways." Financial terms of the agreement were not …
SPONSORED CONTENTUncompromising renal + sensitivities care.Help manage sensitivities + chronic kidney disease with the power of Prescription Diet k/d + z/d Hydrolyzed. + Learn More
The Immunity Challenge: Vaccines and petsJune 22, 2017Back in the day, dog and cat vaccines were cut and dry, and all pets were vaccinated annually, except perhaps for very old or sick animals. Today, the subject is much more fluid, as more information comes to light regarding duration of immunity, potential negative outcomes from vaccinating too often and adverse vaccine events.
Chinese vaccine lab to move into KC Animal Health CorridorJune 1, 2017KC Animal Health Corridor of Kansas City, Mo., will soon be getting some new neighbors in its new K-State Office Park Phase II building. That’s because Jinyu Bio-technology Co., Ltd. (also known as Jinyu Corp), has announced will open a vaccine research lab and office in the new building in 2018.
New feline core vaccine available from BIVIAugust 18, 2016Boehringer Ingelheim Vetmedica Inc. has released a reduced-volume core vaccine for cats. The nonadjuvanted Ultra Hybrid FVRCP is administered in a 0.5 mL subcutaneous dose to protect against feline herpesvirus, calicivirus infection and distemper in cats at least 8 weeks old.
